Q1 2026 · 13F-HR
Lion Point Capital, LPholdings as filed
Filed 2026-05-15 · accession 0001013594-26-000605
$16.7M
Reported value
35
Positions
2026-03-31
Period end
The Brief · Lion Point Capital, LP · Q1 2026
AI · grounded in 13F
Lion Point Capital, LP closed its position in Day One Biopharmaceuticals I DAWNGBX, reducing its holdings by $391,440. The fund also exited positions in Ventyx Biosciences Inc VTYXUSD for $374,745 and Minerva Neurosciences Inc NERV for $140,700. On the buy side, the fund increased its stake in Compass Pathways PLC CMPS by 37.931%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $1.4M | 8.57% | 4,450 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $1.3M | 7.52% | 67,500 | Common | SOLE |
| G7709Q104 | RPRX | ROYALTY PHARMA PLC | $1.0M | 6.14% | 21,400 | Common | SOLE |
| 59935V107 | MIST | MILESTONE PHARMACEUTICALS IN | $975,800 | 5.83% | 820,000 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $861,220 | 5.15% | 578,000 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $840,960 | 5.03% | 36,000 | Common | SOLE |
| 039697107 | ARDX | ARDELYX INC | $770,614 | 4.61% | 128,650 | Common | SOLE |
| 31447P100 | FENC | FENNEC PHARMACEUTICALS INC | $691,469 | 4.13% | 112,434 | Common | SOLE |
| 08205P209 | BNTC | BENITEC BIOPHARMA INC | $660,300 | 3.95% | 62,000 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $620,160 | 3.71% | 28,500 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $517,914 | 3.10% | 8,100 | Common | SOLE |
| 22978P106 | CUE1EUR | CUE BIOPHARMA INC | $506,436 | 3.03% | 2,202,854 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $442,400 | 2.64% | 80,000 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $437,382 | 2.61% | 51,700 | Common | SOLE |
| 516544103 | LNTH | LANTHEUS HLDGS INC | $417,175 | 2.49% | 5,500 | Common | SOLE |
| 471871202 | JSPR | JASPER THERAPEUTICS INC | $407,433 | 2.44% | 465,000 | Common | SOLE |
| 44486Q103 | HUMA | HUMACYTE INC | $394,355 | 2.36% | 650,000 | Common | SOLE |
| 92556V106 | VTRS | VIATRIS INC | $374,227 | 2.24% | 27,700 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $373,980 | 2.24% | 46,000 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $371,300 | 2.22% | 5,000 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $326,340 | 1.95% | 18,000 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $307,880 | 1.84% | 86,000 | Common | SOLE |
| 695127100 | PCRX | PACIRA BIOSCIENCES INC | $305,100 | 1.82% | 13,500 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $286,650 | 1.71% | 9,100 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $284,445 | 1.70% | 10,500 | Common | SOLE |
| 81750R201 | MCRB | SERES THERAPEUTICS INC | $280,026 | 1.67% | 31,570 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $264,100 | 1.58% | 19,000 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $240,345 | 1.44% | 14,700 | Common | SOLE |
| 75901B107 | RGNX | REGENXBIO INC | $222,908 | 1.33% | 26,600 | Common | SOLE |
| 114340102 | AZTA | AZENTA INC | $204,961 | 1.22% | 9,700 | Common | SOLE |
| 45781M101 | INVA | INNOVIVA INC | $191,060 | 1.14% | 8,200 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $143,412 | 0.86% | 10,200 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $123,690 | 0.74% | 5,250 | Common | SOLE |
| 45781K204 | IPHA | INNATE PHARMA S A | $103,873 | 0.62% | 81,151 | Common | SOLE |
| 85209E208 | SPRB | SPRUCE BIOSCIENCES INC | $65,350 | 0.39% | 1,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.